Zhai, Yifan

Discovery of 4-((3′ R ,4′ S ,5′ R )-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 211

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Fang, D. D., Tang, Q., Kong, Y., Wang, Q., Gu, J., Fang, X., Zou, P., Rong, T., Wang, J., Yang, D., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCancer-related Molecular Pathways

Cited by 151

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Jiang, Q., Li, Z., Qin, Y., Li, W., Xu, N., Liu, B., Zhang, Y., Meng, L., Zhu, H., Du, X., et al. (2022) · Journal of Hematology & Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 102

A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma

Yi, H., Yan, X., Luo, Q., Yuan, L., Li, B., Pan, W., Zhang, L., Chen, H., Wang, J., Zhang, Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research

Cancer-related Molecular PathwaysGastric Cancer Management and Outcomes

Cited by 71

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Fang, D. D., Tang, Q., Kong, Y., Rong, T., Wang, Q., Li, N., Fang, X., Gu, J., Xiong, D., Yin, Y., et al. (2021) · Cell Death Discovery

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 58

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial

Jabbour, E., Oehler, V. G., Koller, P. B., Jamy, O., Lomaia, E., Hunter, A. M., Uspenskaya, O., Samarina, S., Mukherjee, S., Cortes, J. E., et al. (2025) · JAMA Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 33

Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.

Tolcher, A. W., Reeves, J. A., McKean, M., Chmielowski, B., Beck, J. T., Shaheen, M. F., Somaiah, N., Wilson, M., Spira, A. I., Drabick, J. J., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCancer-related Molecular Pathways

Cited by 23

Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research

Kantarjian, H., Zhai, Y., Oehler, V. G., Jamy, O., Koller, P. B., Haddad, F. G., Sasaki, K., & Jabbour, E. J. (2025) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 10